Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis
Clinical Study on Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Sepsis
About This Trial
The primary objective: To evaluate the efficacy of intravenous infusion of universal UC-MSCs and CD83+MSCs subpopulation injection in the treatment of sepsis by using the 28-day survival rate of the subjects as the primary efficacy criterion.The secondary objectives: 1. To systematically evaluate the safety of universal UC-MSCs and CD83+MSCs subpopulation in the treatment of sepsis; 2. To provide theoretical basis and clinical research data for establishing a safe, effective and feasible clinical treatment plan for sepsis using stem cells.
Who May Be Eligible (Plain English)
Original Eligibility Criteria
View original clinical language
Treatments Being Tested
CD83-positive MSC
90 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment
regulatory MSC
45 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment
control solution
45 patients are infused with equal volume of control solution and receive regulatory treatment